Protagonist Therapeutics, Inc Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-06-30 was 92.05K shares, a 30.18% decline year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2023-03-31 was 128.72K shares, a 22.22% decline year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2022-12-31 was 140.84K shares, a 15.50% decline year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2022-09-30 was 80.95K shares, a 38.19% decline year-over-year.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 1.06M shares, a 39.91% decline from fiscal 2024.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 1.77M shares, a 411.31% increase from fiscal 2023.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 345.41K shares, a 33.46% decline from fiscal 2022.
- Protagonist Therapeutics, Inc share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 519.11K shares, a 9.33% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2025-12-31 | 1.06M shares 10-K · filed 2026-02-25 | |
| 2024-12-31 | 1.77M shares 10-K · filed 2025-02-21 | |
| 2023-12-31 | 345.41K shares 10-K · filed 2024-02-27 | |
| 2023-06-30 | 92.05K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | 442.57K shares derived: sum of 4 quarters · filed 2023-08-03 |
| 2023-03-31 | 128.72K shares 10-Q · filed 2023-05-04 | 482.35K shares derived: sum of 4 quarters · filed 2023-05-04 |
| 2022-12-31 | 140.84K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | 519.11K shares 10-K · filed 2023-03-15 |
| 2022-09-30 | 80.95K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | 544.95K shares derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | 131.83K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | 594.97K shares derived: sum of 4 quarters · filed 2022-08-04 |
| 2022-03-31 | 165.49K shares 10-Q · filed 2022-05-05 | 546.14K shares derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | 166.68K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | 474.80K shares 10-K · filed 2022-02-28 |
| 2021-09-30 | 130.97K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | 344.65K shares derived: sum of 4 quarters · filed 2021-11-03 |
| 2021-06-30 | 83.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | 357.58K shares derived: sum of 4 quarters · filed 2021-08-04 |
| 2021-03-31 | 94.15K shares 10-Q · filed 2021-05-04 | 359.22K shares derived: sum of 4 quarters · filed 2021-05-04 |
| 2020-12-31 | 36.52K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | 294.24K shares 10-K · filed 2021-03-10 |
| 2020-09-30 | 143.91K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | 268.92K shares derived: sum of 4 quarters · filed 2020-11-04 |
| 2020-06-30 | 84.64K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | 325.24K shares derived: sum of 4 quarters · filed 2020-08-06 |
| 2020-03-31 | 29.17K shares 10-Q · filed 2020-05-07 | 293.98K shares derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | 11.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | 307.06K shares 10-K · filed 2020-03-10 |
| 2019-09-30 | 200.23K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | |
| 2019-06-30 | 53.39K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | |
| 2019-03-31 | 42.24K shares 10-Q · filed 2019-05-08 | |
| 2018-09-30 | 37.60K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | |
| 2018-06-30 | 53.90K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | |
| 2018-03-31 | 50.51K shares 10-Q · filed 2018-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |